Postdoc in immunotherapy for cross-allergic diseases based on mRNA-LNPs - DTU Bioengineering

Allergic diseases affect 30 to 40% of the global population, and many patients are polysensitised, reacting to multiple structurally related allergens due to cross-reactivity. Current allergen immunotherapy requires 3 to 5 years of repeated exposure, often causes adverse reactions, and typically targets only one allergen at a time.

We are working on a translational project combining allergen design with mRNA lipid nanoparticle (LNP)-based delivery to generate broadly protective immune responses against cross-reactive allergen families, starting with nsLTP-mediated food and pollen allergy.

We seek a highly motivated Postdoctoral Researcher with strong immunology and molecular biology expertise to lead formulation optimisation and indication expansion for our mRNA-LNP allergen immunotherapy platform, with the aim of spinning out the project as a startup company in the future.

Responsibilities and qualifications You will play a central role in translating consensus allergen designs into a validated mRNA-LNP therapeutic candidate. Your responsibilities will include: mRNA-LNP formulation screening and characterisation, in collaboration with our LNP formulation partne1 …